Table 2.
Influence of Co-Morbid Anxiety Disorder on Depression Severity and Treatment Outcomes
| |
Anxiety disorder (n = 106) |
No anxiety disorder (n = 203) |
||||
|---|---|---|---|---|---|---|
| Fluoxetine (n = 55) | Placebo (n = 35) | Total (n = 90) | Fluoxetine (n = 102) | Placebo (n = 117) | Total (n = 219) | |
| Baseline CDRS-R (SD) | 61.1 (11.0) | 62.0 (13.0) | 61.4 (11.4) | 55.8 (9.5) | 54.1 (10.3) | 54.9 (10.0) |
| Exit CDRS-R (SD) | 37.7 (15.8) | 49.3 (17.2) | 42.2 (17.3) | 35.3 (12.7) | 40.2 (13.5) | 37.9 (13.3) |
| Response (n)a | 58.1% (32) | 37.1% (13) | 50.0% (45) | 51.0% (52) | 35.9% (42) | 42.9% (94) |
| Remission (n)b | 32.7% (18) | 17.1% (6) | 26.7% (24) | 41.1% (42) | 19.66 (23) | 29.68 (65) |
a
Response based on Clinical Global Impressions–Improvement.
b
Remission based on Children's Depression Rating Scale–Revised.
Abbreviations: CDRS-R = Children's Depression Rating Scale–Revised; SD = standard deviation.